Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection
José Javier Morales-Núñez,
José Francisco Muñoz-Valle,
Carlos Meza-López,
Lin-Fa Wang,
Andrea Carolina Machado Sulbarán,
Paola Carolina Torres-Hernández,
Martín Bedolla-Barajas,
Brenda De la O-Gómez,
Paulina Balcázar-Félix,
Jorge Hernández-Bello
Affiliations
José Javier Morales-Núñez
Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico
José Francisco Muñoz-Valle
Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico
Carlos Meza-López
Pediatric Service, Nuevo Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”, University of Guadalajara, Guadalajara 44340, Mexico
Lin-Fa Wang
Programmed in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore
Andrea Carolina Machado Sulbarán
Institute for Research on Cancer in Childhood and Adolescence, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico
Paola Carolina Torres-Hernández
Immunology Laboratory, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico
Martín Bedolla-Barajas
Allergy and Clinical Immunology Service, Nuevo Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”, University of Guadalajara, Guadalajara 44340, Mexico
Brenda De la O-Gómez
University Center for Exact Sciences and Engineering (CUCEI), University of Guadalajara, Guadalajara 44340, Mexico
Paulina Balcázar-Félix
Immunology Laboratory, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico
Jorge Hernández-Bello
Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico
The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the first to be authorized in the USA and Mexico (11 December 2020). This study evaluated the efficacy of this vaccine on antibody production with neutralizing capacity and its side effects in healthcare workers with and without prior SARS-CoV-2 infection and in a group of unvaccinated individuals with prior COVID-19. The main findings are the production of 100% neutralizing antibodies in both groups after the second dose, well-tolerated adverse effects, the possible presence of immunosenescence, and finally, we support that a single dose of this vaccine in individuals with prior COVID-19 would be sufficient to achieve an immunization comparable to people without prior COVID-19 with a complete vaccination program (2 doses).
